---
schema_version: "secwatch.filing_event.v1"
accession: "0001232524-23-000014"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2023-03-01T23:59:59+00:00"
generated_at: "2026-06-18T17:08:34.811229+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Jazz Pharma reports record 2022 revenue of $3.7B, up 18% YoY; guides 2023 revenue $3.675-3.875B

## Summary
- Record 2022 total revenue $3.7B (+18% YoY); 2023 revenue guidance $3.675-3.875B (3% growth at midpoint).
- Xywav became largest product in Q4, annualizing >$1B; more narcolepsy patients on Xywav than Xyrem.
- Cash from operations $1.3B in 2022; delevered balance sheet to 2.9x adjusted net leverage.
- Pipeline progress: positive zanidatamab pivotal trial in BTC; Phase 2 suvecaltamide in Parkinson's tremor enrolled.
- FDA approved Rylaze sBLA for MWF IM dosing; Epidyolex launched in all five key EU markets.

## SEC filing metadata
- accession: 0001232524-23-000014
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2023-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000123252423000014/0001232524-23-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000123252423000014/jazz-20230301.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001232524-23-000014
- JSON: https://secwatch.observer/filing/0001232524-23-000014.json
- Plain text: https://secwatch.observer/filing/0001232524-23-000014.txt

## Key facts
- Earnings Releases
  Jazz Pharmaceuticals plc reported full year 2023 results: revenue $3,675 to $3,875 million. Guidance initiated.
  - Period: full year 2023
  - Revenue: $3,675 to $3,875 million
  - Guidance: initiated
  - Result: guidance update
  source text: 2023 total revenue guidance of $3,675 to $3,875 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1232524/000123252423000014/0001232524-23-000014-index.htm
- Earnings Releases
  Jazz Pharmaceuticals plc reported full year and fourth quarter ended December 31, 2022 results: revenue $3.7 billion.
  - Period: full year and fourth quarter ended December 31, 2022
  - Revenue: $3.7 billion
  - Result: reported results
  source text: Strong Execution Drove Record Revenues in 2022 of $3.7 billion, an increase of 18% over 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1232524/000123252423000014/0001232524-23-000014-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.